Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 551-556

  Maeda, Junko ^a   Roybal, Erica J ^a   Brents, Colleen A ^a   Uesaka, Mitsuru ^b   Aizawa, Yasushi ^c   Kato, Takamitsu A ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c Research and Development Group   (Japan)

Author keywords

BRCA2; Flavonoid; PARP inhibitor

Indexed keywords

BRCA2 PROTEIN; DOUBLE STRANDED DNA; FLAVONOID; MALTOOLIGOSYL RUTIN; MONOGLUCOSYL RUTIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; QUERCETIN; RUTOSIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENETIC COMPLEMENTATION; HAMSTER; IN VITRO STUDY; LETHALITY; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; BRCA2 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETULUS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; POLY(ADP-RIBOSE) POLYMERASES; QUERCETIN; RUTIN;

EID: 84892389277     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2902     Document Type: Article

References (33)

1. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM and Lines TC: A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45: 2179-2205, 2007.
2. Day AJ and Williamson G: Biomarkers for exposure to dietary flavonoids: a review of the current evidence for identification of quercetin glycosides in plasma. Br J Nutr 86 (Suppl 1): S105-S110, 2001.
3. Boots AW, Haenen GR and Bast A: Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585: 325-337, 2008.
4. Matsukawa N, Matsumoto M, Chiji H and Hara H: Oligosaccharide promotes bioavailability of a water-soluble flavonoid glycoside, αG-rutin, in rats. J Agric Food Chem 57: 1498-1505, 2009.
5. Chen YW, Chou HC, Lin ST, et al: Cardioprotective effects of quercetin in cardiomyocyte under ischemia/reperfusion injury. Evid Based Complement Alternat Med 2013: 364519, 2013.
6. Bakhshaeshi M, Khaki A, Fathiazad F, Khaki AA and Ghadamkheir E: Anti-oxidative role of quercetin derived from Allium cepa on aldehyde oxidase (OX-LDL) and hepatocytes apoptosis in streptozotocin-induced diabetic rat. Asian Pac J Trop Biomed 2: 528-531, 2012.
7. Lee KH and Yoo CG: Simultaneous inactivation of GSK-3β suppresses quercetin-induced apoptosis by inhibiting the JNK pathway. Am J Physiol Lung Cell Mol Physiol 304: L782-L789, 2013.
8. Romano B, Pagano E, Montanaro V, Fortunato AL, Milic N and Borrelli F: Novel insights into the pharmacology of flavonoids. Phytother Res: July 4, 2013 (Epub ahead of print).
9. Duraj J, Zazrivcova K, Bodo J, Sulikova M and Sedlak J: Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma 52: 273-279, 2005.
10. Nijman SMB: Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett 585: 1-6, 2011.
11. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917, 2005.
12. Basu B, Sandhu SK and de Bono JS: PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 72: 1579-1590, 2012.
13. Poitras MF, Koh DW, Yu SW, et al: Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain. Neuroscience 148: 198-211, 2007.
14. Polyak K and Garber J: Targeting the missing links for cancer therapy. Nat Med 17: 283-284, 2011.
15. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A and Reis-Filho JS: Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 10: 1192-1199, 2011.
16. Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, et al: PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 47: 13-26, 2009.
17. Brandt A, Lorenzo Bermejo J, Sundquist J and Hemminki K: Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start? Breast Cancer Res Treat 121: 133-141, 2010.
18. Iqbal J, Ragone A, Lubinski J, et al: The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 107: 2005-2009, 2012.
19. Christopoulou A and Spiliotis J: The role of BRCA1 and BRCA2 in hereditary breast cancer. Gene Ther Mol Biol 10A: 95-99, 2006.
20. Whittemore AS, Gong G, John EM, et al: Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 13: 2078-2083, 2004.
21. Mavaddat N, Barrowdale D, Andrulis IL, et al: Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21: 134-147, 2012.
22. Teng LS, Zheng Y and Wang HH: BRCA1/2 associated hereditary breast cancer. J Zhejiang Univ Sci B 9: 85-89, 2008.
23. Verhaegh GW, Jongmans W, Morolli B, et al: A novel type of X-ray-sensitive Chinese hamster cell mutant with radioresistant DNA synthesis and hampered DNA double-strand break repair. Mutat Res 337: 119-129, 1995.
24. Geraets L, Moonen HJ, Brauers K, Wouters EF, Bast A and Hageman GJ: Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. J Nutr 137: 2190-2195, 2007.
25. Kanai Y, Tanuma S and Sugimura T: Immunofluorescent staining of poly(ADP-ribose) in situ in HeLa cell chromosomes in the M phase. Proc Natl Acad Sci USA 78: 2801-2804, 1981.
26. Kuo LJ and Yang LX: γ-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo 22: 305-309, 2008.
27. Matsuo M, Sasaki N, Saga K and Kaneko T: Cytotoxicity of flavonoids toward cultured normal human cells. Biol Pharm Bull 28: 253-259, 2005.
28. Boege F, Straub T, Kehr A, et al: Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J Biol Chem 271: 2262-2270, 1996.
29. Spencer JP, Abd-el-Mohsen MM and Rice-Evans C: Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. Arch Biochem Biophys 423: 148-161, 2004.
30. Ishikawa M, Oikawa T, Hosokawa M, Hamada J, Morikawa K and Kobayashi H: Enhancing effect of quercetin on 3-methylcholanthrene carcinogenesis in C57Bl/6 mice. Neoplasma 32: 435-441, 1985.
31. Venskutonis PR, Dedonyte V, Lazutka J, et al: A preliminary assessment of singlet oxygen scavenging, cytotoxic and genotoxic properties of Geranium macrorrhizum extracts. Acta Biochim Pol 57: 157-163, 2010.
32. Nakayama T, Yamada M, Osawa T and Kawakishi S: Suppression of active oxygen-induced cytotoxicity by flavonoids. Biochem Pharmacol 45: 265-267, 1993.
33. Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244, 2010.